Intellia Therapeutics IncChange company Symbol lookupSelect an option...NTLA Intellia Therapeutics IncWOLF Wolfspeed IncLCID Lucid Group IncAMAT Applied Materials Inc$DWCPAP DJTSM US PaperCMMB Chemomab Therapeutics LtdDLTR Dollar Tree IncBAC Bank of America CorpKW Kennedy-Wilson Holdings IncRAND Rand Capital CorpGo
Change company Symbol lookup
Select an option...
NTLA Intellia Therapeutics Inc
WOLF Wolfspeed Inc
LCID Lucid Group Inc
AMAT Applied Materials Inc
$DWCPAP DJTSM US Paper
CMMB Chemomab Therapeutics Ltd
DLTR Dollar Tree Inc
BAC Bank of America Corp
KW Kennedy-Wilson Holdings Inc
RAND Rand Capital Corp
Health Care : Biotechnology | Small Cap Blend
Company profileIntellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE). It is developing ex vivo applications to address immuno-oncology and autoimmune diseases. Its advanced ex vivo programs include a wholly owned chimeric antigen receptor T (CAR-T) cell candidate, NTLA-6001 targeting CD30 for the treatment of CD30-expressing hematologic cancers, including relapsed or refractory classical Hodgkin's lymphoma.
|
|
|
|
| |
| Latest Earnings Beat Consensus (Q1 ending 03/2023) | Next Earnings Announcement | ||||||
|---|---|---|---|---|---|---|---|
| Q1 Non-GAAP earnings GAAP vs. Non-GAAP EarningsTD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. Announced May 4, 2023 | -$1.17 | Q1 Consensus of 25 analysts | -$1.40 | Difference from consensus | 16.43% | Q2 Earnings will announce | (Unconfirmed) August 2, 2023 |
Quarterly Earnings History and Estimates
Show high-low estimates
Draw trendlines
Draw up to 3 lines inside the chart.
NTLA's fiscal year ends in December
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.